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In this retrospective cohort study, oral glucose tolerance testing (OGTT) was performed for all 
enrolled survivors of patients who suffered from acute lymphoblastic leukemia (ALL) at least 9 
months after ending chemotherapy, as well as for control group. All demographic, treatment and 
anthropomorphic data were obtained from medical records. Furthermore, insulin resistance was 
evaluated according to insulin level, Matsuda and HOMA-IR index. Of 53 subjects, 28 exhibited 
B-cell ALL, and 25 were healthy children (F/M = 1.12/1). Mean age (±SD) was determined to be 
10.77 ± 2.83 years, and meantime off for therapy was also recorded as 3.0 ± 1.6 years. ALL 
patients were diagnosed at age 1–15 years; none of them received the cranial radiotherapy, and 
demographic characteristics (age, sex, and sexual maturity) were found to be the same in both 
groups. Seven patients showed transient hyperglycemia during ALL treatment, however, no 
significant differences were found in terms of body mass index (BMI) means between ALL 
patients with and without transient hyperglycemia. Based on the data presented herein, insulin 
resistance could not be predicted by glucose levels during therapy, cumulative asparaginase, and 
steroid. Our findings demonstrated that elevated BMI could be a valuable predictor of insulin 
resistance probability in ALL patients. The presence of transient hyperglycemia does not appear to 
be associated with the increased risk of glucose intolerance or insulin resistance in the first few 
years after completion of therapy. 




Advances in the treatment of children with ALL have led to marked improvements in survival, 
where there is an expanding list of chemotherapy drugs. Increasing the survival of these children 
has raised new concerns, especially about the long-term side effects of these drugs. Many studies 
have emphasized the incidence of these complications, especially in the elderly such as obesity 
and abnormal weight 
1
. Furthermore, disturbances in blood lipid profile, hyperglycemia, and 
insulin resistance are other known complications 
2
. These abnormalities can lead to deadly 
cardiovascular disease and type 2 diabetes in these patients 
3
. Despite the high prevalence of 
these complications and the poor prognosis of these abnormalities, studies in this field have not 
yet been able to specifically identify the major risk factors for hormonal imbalances 
4
.  
Studies have shown that two of the important drugs used to treat these patients are corticosteroids and 
asparaginase. Hyperglycemia is a common complication for both drug groups, most commonly 
in the induction phase of treatment, because both drugs are used concurrently. It was found to be 
capable of developing transient hyperglycemia and could be most frequently occurred in patients 
with obesity, Down syndrome, a family history of diabetes, and over 10 years of age 
5
. Contrary 
to the severity of the complication, transient hyperglycemia improves without compromising the 
patient. Although many studies confirm that those treated usually have high FBS and insulin 
resistance, they could not prove metabolic complications following transient hyperglycemia. The 
efficacy of different therapeutic approaches and different doses of medication on the incidence of 
these complications have not been well understood in previous studies. Therefore, prognostic 
markers may be capable of preventing the full onset of the complication 
6
.  
         
 
 
On the other hand, the treatment of complications such as diabetes is not completely possible and 
its symptoms lead to high costs and wasted manpower. Therefore, interest has focused markedly on 
the prevention aspects and identification of prognostic markers is of great importance in 
preventing these complications. BMI is a more important indicator in this regard 
7
. BMI 
calculation is a simple, inexpensive and affordable index. Nevertheless, if this index is power-
full, it may be used as an appropriate, available, and mandatory index in predicting the hormonal 
complications of chemotherapy, and all subsequent follow-up of these patients
8,9
. As a result, it 
is likely to be capable of preventing the severity of secondary hormonal complications such as 
diabetes, obesity by subsequent preventive therapies 
10
. 
On the other hand, the components of the BMI index, height, and weight, are also affected by 
repeated chemotherapy. Some studies reported lower stature growth in these children as 
compared to normal children 
11
 and others pointed to excessive weight gain in them. These 
components (i.e., height in childhood and weight even at an older age) are highly modifiable, 
therefore, the imbalance in this index can be reduced by modifying the above risk factors for 
cardiovascular complications and diabetes 
12,13. 
Materials and methods 
This retrospective (historical) cohort was conducted in Ali-Asghar Medical Center, Tehran, Iran. 
Children treated for ALL with complete medical records were enrolled in the study who had 
elapsed after their treatment for at least 9 months and were referred for follow-up care. Convenience 
sampling was considered based on the medical records of patients admitted to the hospital with 
ALL. 
Inclusion criteria included 1- Age at diagnosis between 0 and 15 years, 2- Having informed 
consent, 3. Diagnosis of lymphoblastic leukemia. Exclusion criteria included 1- Incomplete 
medical records (> 20% of all information), 2. Children with relapsed or metastatic disease. 
Since the principle of this scheme calculates the correlation between the two quantitative 
amounts of BMI and insulin resistance, the lowest r calculated in the study was 0.03. According 
to the formula, if the first type error by 5% with a study power of 80%, the number of samples can 
be calculated as follows 
  (Za-Zb/C)+3=n 
 C= 0.5* Ln(1+0.3/1-0.3(, N=62 
The initial sample size is assumed to be at most 60 (50 to 60) to prevent potential plan problems 
and to avoid decreasing study power due to difficulties.  
In the first step, patients' data were extracted from their medical records, including date of 
diagnosis, age at diagnosis, highest blood glucose obtained during treatment, cumulative doses of 
corticosteroid and asparagine, type of disease (B-cell or T-cell).  
These two criteria (height and weight at diagnosis) are used to calculate the patient's BMI at 
diagnosis. According to the Centers for Disease Control and Prevention (CDC) criteria, a BMI 
greater than or equal to 85% is considered a risk factor for overweight and a BMI greater than 
95% for age is considered overweight. In the second step, medical records of children as those 
listed above were extracted and followed upped after treatment. Informed consent was obtained 
from patients' parents. All patients were fasted for at least 12 hours, then their blood glucose, 
         
 
 
fasting insulin and HbA1C values were measured. Their blood samples were taken 0, 60, and 
120 minutes after taking 1.75 mg/kg of oral glucose solution. Based on these samples, glucose 
metabolism was calculated and insulin-resistant disease was diagnosed based on the fasting 
insulin of >115 mU/m or a maximum blood insulin level of > 150 mU/ml. To further investigate 
insulin resistance, the HOMA and Matsuda criteria were also calculated for patients. The HOMA 
index is based on insulin resistance of >4 in adolescents and children and >2.5 in adults (HOMA-
IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose 
(nmol/L)/22.5). Matsuda index was determined for expressing rd values (Rate of Disapearence of 
Plasma Glucose) by the glucose clamp technique. The Matsuda index was calculated according 
to the formula: 10000 / √(FPI* FPG) * (xGPC* xIPC); Where FPI is fasting plasma insulin 
expressed as uU/ml, FPG is fasting plasma glucose expressed as mg/dL, xGPC is mean plasma 
glucose concentration after the load and xIPC is the mean insulin concentration after the load). 
According to published results, patients without insulin resistance have a Matsuda index of ≥3. 
FBS ≥126 mg/dL was considered for diabetes or blood glucose of 200 two hours after glucose 
consumption. FBS levels of 100–125 mg/dl; or blood glucose of >140 two hours post-consumption of 
glucose. 




Of the 53 patients, 28 were ALL patients and 25 healthy controls. All patients showed B-cell 
disease and none of the patients had CRT. Type of regimen was the same in all patients and 
cumulative doses of corticosteroid and asparagine were determined on the same basis. 
Demographic characteristics of the two groups 
In the present study, the mean age of ALL patients and the control group were determined as 
10.45± 3.041 years and 11.13± 2.587 years, respectively. The mean age of the patients was 
10.77± 2.83 years. According to the t-test results, there was no significant difference between the 
ALL and control groups in terms of age (Chi-Square Tests = 0.976 and P = 0.323). The 
frequency of puberty status is summarized in Table 3. The majority of immature individuals 
belonged to ALL patients (14%, 50%), followed by the control group (11%; 44%). Based on the 
results presented in Table 1, no significant difference was found between the two groups in terms 
of maturity status (Chi-Square Tests = 1.487 and P = 0.475). 
Table 1: Frequency of puberty status in ALL and control groups 
 ALL Control group 
 Frequency Percentage in 
group 




Immature 14 50 11 44 
Middle 
Maturity 
6 4.21 9 36 
Mature 8 6.28 5 20 
 
         
 
 
The mean cumulative doses of corticosteroid and asparagine in all patients with ALL are 
presented in Table 2. An average dose of 53742.86 mg /m
2
 was determined for asparagine and 
1065.7 mg /m
2
 for corticosteroids. 
Table 2: Mean cumulative doses of corticosteroid and asparagine in ALL patients 
  (mg/m
2
)  Mean Number Minimum  Maximum  SD 
asparagine 86.53742 28 35200 96800 309.15584 
Corticosteroid 70.1065 28 698 1920 030.309 
 
The mean weight was also recorded as 36.11 ± 14.114 kg and 42.76 ± 11.281 kg for ALL and 
control groups, respectively. Furthermore, the mean height was found to be 136.86 ± 16.46 cm in 
the ALL group and 143.52 ± 11.276 cm in the control group. There was no significant difference 
in weight and height between the ALL and healthy groups (Weight: T rest = - 1.880 and P = 
0.066), (Height: T test= - 1.698 and P = 0.096). The mean BMI in the ALL and healthy groups 
was also calculated as 18.8 ± 2.805 and 20.49 ± 3.952, respectively. The mean BMI of all 
patients was calculated to be 19.6 ± 3.467 (minimum = 13.3 and maximum = 28). However, no 
significant difference was observed between the two groups in terms of BMI (T = - 1.816 and P 
= 0.075). 
The mean BMI SDS of patients was evaluated in Table 3. BMI SDS was used to remove the 
effect of age and sex on BMI and values above 1.28 were considered obese. Overall, the mean 
BMI SDS of the patients was determined 0.63± 0.879 (minimum = - 0.94 and maximum = 2.66), 
which is presented in Table 3 along with the standard deviation in the ALL and control groups. 
Based on the findings presented herein, no significant difference was seen between the two 
groups in terms of SDS BMI (T = - 0.874 and P = 0.386). 
 
Table 3: Mean BMI SDS in ALL and control groups 
 Mean 
BMI SDS 
Number Minimum Maximum SD 
ALL 53.0 28 94.0- 66.2 834.0 
Normal 74.0 25 90.0- 15.2 930.0 
 
The Frequency of BMI staging status was evaluated in the present study. Our findings showed 
that lower BMI was seen in 15 (53.6%) out of 53 ALL patients, followed by normal range (12 
patients, 42.9%) and out of normal range (3.6%, 1 subject). In the control group, 8 (32%) showed 
lower BMI, followed by normal range (14 patients, 56%) and out of normal range (3 patients, 
12%). No significant difference was found between the ALL and control groups regarding BMI 
staging status (Chi-Square Tests = 3.124, P = 0.210). 
Table 4 shows the frequency of insulin resistance status. The frequency of insulin resistance 
status based on insulin levels, Matsuda index and HOMA index are indicated in Table 4. No 
significant difference was found between the two groups in terms of insulin resistance based on 
insulin levels, Matsuda and HOMA indices. 




Table 4: Frequency of insulin resistance based on blood sugar levels 
 ALL Control Chi-square 












9 32.1 8 32 000.0 991.0 
Matsuda 
Index 
3 10.7 3 12 022.0 883.0 
HOMA 
index 
6 21.4 5 20 016.0 585.0 
 
Correlation of BMI increase with Matsuda and HOMA criteria was evaluated in the ALL treated 
group (Table 5). There was a significant relationship between insulin resistance and its absence 
in terms of Matsuda index, HOMA, and BMI in ALL treated patients, where the kappa 
coefficient was positive for all three indices. 
Table 5: Relationship between BMI increase and Matsuda and HOMA indices 
BMI increase  Yes No Chi-square Risk estimate Kappa 
  no (%) no (%)  χ






yes 3 (25) 9 (75) 480.4 034.0 2.778 1.647 4.685 117.2 
no 0 16 (100) 
HOMA 
index 
yes 6 (100) 6 (27.3) 182.10 001.0 3.667 1.853 7.255 191.3 
no 0 16 (72.7) 
Total yes 6 (100) 6 (27.3) 182.10 001.0 3.667 1.853 7.255 191.3 
no 0 16 (72.7) 
 
Table 6 compares BMI with Matsuda and Homa criteria in the healthy group, where no 
significant relationship was found between insulin resistance and its absence according to 
Matsuda index, HOMA, and BMI in the healthy group. Kappa coefficient was found to be 
negative for all three indices. 
Table 6: Relationship of BMI increase with Matsuda and HOMA indices 



















Yes 0 0 8 4.36 604/1 205.0 267.1- 
No 3 100 14 63.6 
HOMA 
index 
Yes 0 0 8 40 941/2 086.0 715.1- 
No 5 100 12 60 
Total Yes 3 25 5 38.5 502/0 471.0 721.0- 
No 9 75 8 61.5 
 
         
 
 
The relationship between transient hyperglycemia in ALL treated patients was investigated 
during treatment and insulin resistance (Table 7). The frequency of insulin resistance status 
based on insulin levels, Matsuda index and HOMA index among 28 treated ALL patients 
without hyperglycemia during treatment are presented in Table 7. No significant difference was 
revealed between the two groups with and without transient hyperglycemia in terms of insulin 
resistance status. 
Table 7: Frequency of insulin resistance based on blood sugar levels 
 Hyperglycemic No hyperglycemia Chi-square 











Insulin level 0 0 0 0 - - 
Matsuda 
Index 
0 0 3 3.14 120.1 290.0 
Index 
HOMA 
1 3.14 5 8.23 283.0 595.0 
 
Correlation between BMI increases after treatment of ALL patients with insulin resistance was 
calculated based on Matsuda criteria. Of the 28 ALL patients, 3 insulin resistance patients 
(100%) exhibited high BMI, and 9 (36%) showed high BMI. 
However, 16 (64%) insulin resistance patients showed low BMI. Our findings revealed a 
significant difference between the two groups (with and without BMI) in terms of Matsuda 
criteria (Chi-Square Tests = 4.480 and P = 0.034). According to the HOMA criterion, 6 (100%) 
out of 28 ALL patients with insulin resistance exhibited high BMI and 6 patients without insulin 
resistance (27.3%) had high BMI. The remaining 16 (72.7%) patients without insulin resistance 
revealed no BMI elevation. There was a significant difference between the two groups (with and 
without BMI) in terms of insulin resistance based on Homa criteria (Chi-Square Tests = 10.182 
and P = 0.001).  
The association between post-treatment BMI in ALL treated patients with total insulin resistance 
(based on insulin level, Matsuda's and HOMA criteria) was calculated. The results revealed that 
6 (100%) patients with increased BMI had insulin resistance and 6 patients without insulin 
resistance exhibited increased BMI. Furthermore, 16 patients (72.7%) without increased BMI did 
not show insulin resistance. A significant difference was found between the two groups (with 
and without BMI) in terms of total insulin resistance (based on insulin level, Matsuda criteria, 
and HOMA) (Chi-Square Tests = 10.182 and P = 0.001). The association between BMI 
elevations over one year in healthy subjects with insulin resistance was calculated based on 
Matsuda criteria (Table 8). No significant difference between the two groups (with and without 
BMI) in terms of insulin resistance according to the Matsuda criterion (Chi-Square Tests = 1.604 




         
 
 







Correlation between BMI elevations over one year in healthy subjects with insulin resistance was 
calculated on the basis of HOMA criteria (Table 9). 
There was no significant difference between the two groups (with and without BMI) in terms of 
insulin resistance according to HOMA criteria (Chi-Square Tests = 2.941 and P-value = 0.086). 
 
Table 9: Frequency of BMI increase over one year in healthy individuals based on HOMA 
criteria 
 Insulin resistance based on HOMA criteria 
 
 Yes No 
 Frequency Percentage in group Frequency Percentage in group 
increase BMI Yes 0 0 8 40 
No 5 100 12 60 
 
The association between BMI over one year was calculated for healthy subjects with total insulin 
resistance (based on insulin levels, Matsuda's and HOMA criteria) (Table 10). However, no 
significant difference was observed between the two groups with and without increased BMI in 
terms of total insulin resistance (based on insulin level, Matsuda's and HOMA criteria), (Chi-
Square Tests = 0.520 and P = 0.471). 
Table 10: Frequency of BMI elevation over one year in healthy subjects in terms of total insulin 
resistance  
 Total insulin resistance 
 Yes No 
 Frequency Percentage in group Frequency  Percentage in group 
 increase BMI Yes 3 25 5 5.38 




 Insulin resistance based on Matsuda criteria 
 
 Yes No 
 Frequency Percentage in group Frequency Percentage in group 
increase BMI Yes 0 0 8 4.36 
No 3 100 14 6.63 




ALL is one of the most common childhood malignancies which are accounted for 25% of 
childhood malignancies and 75% of childhood leukemia 
14
. Improved therapeutic strategies 
increase the chances of treatment for these children, but the long-term side effects of 
chemotherapy have raised concerns regarding insulin resistance and obesity. Insulin resistance is 
one of the key features of metabolic syndrome and an early defect in the development of type 2 
diabetes 
15.
 Reports also indicated the role of insulin resistance in the development of the 
cardiovascular disease. Therefore, we assessed the relationship between the BMI index and 
insulin resistance in children treated for leukemia. 
Fifty-three subjects including 28 ALL and 25 healthy individuals were enrolled in the study. 
Patients with ALL showed B-cell disease and none of them had CRT. The treatment regimen 
was the same in all patients and cumulative doses of corticosteroid and asparagine were 
determined according to the protocol. No significant difference was found in demographic 
characteristics between the two groups. In the current study, insulin resistance was evaluated 
based on three criteria including insulin level, Matsuda and HOMA criteria. The association 
between BMI and insulin resistance was evaluated on the basis of each criterion by considering 
the incidence of resistance based on one of the criteria, in two groups. A significant relationship 
was seen between BMI elevation and insulin resistance in ALL treated patients according to 
Matsuda and HOMA criteria, but not in healthy subjects. This may prove that increased BMI can 
be a valuable predictor for insulin resistance probability during the treatment of ALL patients. 
Therefore, proper diet, management of drug complication and modification of treatment 
protocols in such people can be helpful. In 2009, Dr. Roberson and colleagues evaluated 871 
treated children, where 141 children developed transient hyperglycemia during treatment in the 
US. The rate of treatment, overall survival, recurrence in the groups with and without this 
complication did not differ, therefore, this team does not consider this effect as a hindrance to 
current doses of chemotherapy by investigating the short-term side effects of pediatric treatment 
11
.  
In our study, there was no association between transient hyperglycemia in terms of insulin 
resistance among ALL treated patients. 
Correlation of BMI increase with Matsuda and HOMA criteria in both ALL treated and healthy 
groups were evaluated by the chi-square test and Kappa coefficient. Kappa coefficient was found 
to be positive in ALL treated groups, while this statistic was negative for the healthy groups. 
Another study by Chorob and colleagues reported two cases of complication among treated 
patients who both needed hospitalization and insulin use early. They reported a significant 
relationship between the incidences of this complication with the use of asparaginase 
16
. Dr. 
Wang and his colleagues have reported cases of secondary diabetes caused by corticosteroid 
therapy among their patients, all of whom have been forced to start insulin therapy. Polyuria and 
hyperglycemia during treatment have been reported in these patients, consistent with our study 
17
. 
In another study by Lowas et al, nearly 42% of all treated people showed transient 
hyperglycemia, where diabetes and obesity were indicated as the most important secondary and 
long-term side effects. They also found a clear relationship between the use of asparaginase and 
the incidence of this complication. However, this research group did not find a clear link 
between the use of medications and the development of stable diabetes in their subsequent 
research.  




The findings revealed that BMI could be a favorable predictor of insulin resistance probability in 
ALL patients. The presence of transient hyperglycemia does not appear to be associated with the 
increased risk of glucose intolerance or insulin resistance in the first few years after completion 
of therapy. 
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